Search Results - "NAIR, Bijay"

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents by USMANI, Saad Z, HEUCK, Christoph, VAN RHEE, Frits, CROWLEY, John, BARLOGIE, Bart, MITCHELL, Alan, SZYMONIFKA, Jackie, NAIR, Bijay, HOERING, Antje, ALSAYED, Yazan, WAHEED, Sarah, HAIDER, Sajjad, RESTREPO, Alejandro

“…Extramedullary disease is an uncommon manifestation in multiple myeloma and can either accompany newly diagnosed disease or develop with disease progression or…”
Get full text

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients by Szmania, Susann, Lapteva, Natalia, Garg, Tarun, Greenway, Amy, Lingo, Joshuah, Nair, Bijay, Stone, Katie, Woods, Emily, Khan, Junaid, Stivers, Justin, Panozzo, Susan, Campana, Dario, Bellamy, William T, Robbins, Molly, Epstein, Joshua, Yaccoby, Shmuel, Waheed, Sarah, Gee, Adrian, Cottler-Fox, Michele, Rooney, Cliona, Barlogie, Bart, van Rhee, Frits

“…Highly activated/expanded natural killer (NK) cells can be generated by stimulation with the human leukocyte antigen-deficient cell line K562, genetically…”
Get full text

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 by Zhou, Yiming, Chen, Lijuan, Barlogie, Bart, Stephens, Owen, Wu, Xiaosong, Williams, David R, Cartron, Marie-Astrid, van Rhee, Frits, Nair, Bijay, Waheed, Sarah, Pineda-Roman, Mauricio, Alsayed, Yazan, Anaissie, Elias, Shaughnessy, John D. Jr

“…MicroRNAs (miRNAs) are noncoding RNAs that regulate global gene expression. miRNAs often act synergistically to repress target genes, and their dysregulation…”
Get full text

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy by van Rhee, Frits, Szymonifka, Jackie, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Barlogie, Bart

“…The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T), and dexamethasone (D) on overall survival (OS),…”
Get full text

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data by Waheed, Sarah, Mitchell, Alan, Usmani, Saad, Epstein, Joshua, Yaccoby, Shmuel, Nair, Bijay, van Hemert, Rudy, Angtuaco, Edgardo, Brown, Tracy, Bartel, Twyla, McDonald, James, Anaissie, Elias, van Rhee, Frits, Crowley, John, Barlogie, Bart

“…Multiple myeloma causes major morbidity resulting from osteolytic lesions that can be detected by metastatic bone surveys. Magnetic resonance imaging and…”
Get full text

Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma by Agarwal, Abhishek, Singla, Sandeep, Bansal, Meghana, Nair, Bijay

“…Multiple Myeloma is a hematologic malignancy of plasma cell origin. Pleural effusion may develop in the setting of myeloma due to various reasons but is…”
Get full text

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120) by Dhodapkar, Madhav V., Sexton, Rachael, Waheed, Sarah, Usmani, Saad, Papanikolaou, Xenofon, Nair, Bijay, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Orlowski, Robert Z., Barlogie, Bart

“…All cases of clinical myeloma (CMM) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monoclonal gammopathy of undetermined…”
Get full text

Early Infection Risk in Newly Diagnosed Multiple Myeloma Patients in the Modern Era by Stevenson, Ryan, Carpenter, Diane M., Khan, Adnan, Fatoki, Raleigh, Rajagopal, Sumanth, Green, Michael M, Nair, Bijay, Baer, David M.

“…Background: Multiple myeloma (MM) is the second most common hematologic malignancy, with an estimated 30,000 new cases in the United States annually. Advances…”
Get full text

Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices by Law, Lisa Y, Stevenson, Ryan, Ho, Gwendolyn, Nair, Bijay, Laura, Asakura, Sayegh, Antoine

“…▪ Introduction: There are limited options for acute myeloid leukemia (AML) patients who are too frail to receive intensive induction chemotherapy or who have…”
Get full text

Smoldering multiple myeloma progression to multiple myeloma in a community-based population by Fatoki, Raleigh Ayoolu, Carpenter, Diane M., Ramalingam, Nirmala D., Khan, Adnan Ahmed, Nair, Bijay P., Stevenson, Ryan Lloyd, Green, Michael M., Lo, Joan C., Baer, David M.

“…e20015 Background: Few studies have characterized patients with smoldering multiple myeloma (SMM) in ethnically diverse settings and data regarding progression…”
Get full text

Solitary extramedullary and bone plasmacytomas versus multiple myeloma with extramedullary manifestation by Nair, Bijay

Get more information

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance by Nair, Bijay, van Rhee, Frits, Shaughnessy, John D., Anaissie, Elias, Szymonifka, Jackie, Hoering, Antje, Alsayed, Yazan, Waheed, Sarah, Crowley, John, Barlogie, Bart

“…The Total Therapy 3 trial 2003-33 enrolled 303 newly diagnosed multiple myeloma patients and was noted to provide superior clinical outcomes compared with…”
Get full text

Retrospective Review of the Safety and Efficacy of High-Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B-Cell Lymphoma at Kaiser Permanente- Northern California (Jan 2015 - June 2019) by Law, Lisa Y, Dutia, Mrinal, Stevenson, Ryan, Lau, Melanie, Mok, Timothy, Vu, Khoan, Soe, Aye Min, Lopez, Alfredo R., Thomas, Sachdev, Vempaty, Hyma T., Gavini, Aruna, Nair, Bijay

“…Retrospective review of the safety and efficacy of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma at Kaiser Permanente-…”
Get full text

Herpes zoster vaccine and varicella zoster virus infection among cancer patients having chemotherapy by Law, Lisa Y., Carpenter, Diane M., Grigor, Laura M., Nair, Bijay P.

“…Abstract only…”
Get full text

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 by Shaughnessy, John D., Qu, Pingping, Usmani, Saad, Heuck, Christoph J., Zhang, Qing, Zhou, Yiming, Tian, Erming, Hanamura, Ichiro, van Rhee, Frits, Anaissie, Elias, Epstein, Joshua, Nair, Bijay, Stephens, Owen, Williams, Ryan, Waheed, Sarah, Alsayed, Yazan, Crowley, John, Barlogie, Bart

“…Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and dexamethasone test doses showed these agents' mechanisms of action and…”
Get full text

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance by Usmani, Saad Z., Sexton, Rachel, Hoering, Antje, Heuck, Christoph J., Nair, Bijay, Waheed, Sarah, Al Sayed, Yazan, Chauhan, Nabeel, Ahmad, Nisar, Atrash, Shebli, Petty, Nathan, van Rhee, Frits, Crowley, John, Barlogie, Bart

“…Thalidomide and lenalidomide constitute an important part of effective myeloma therapy. Recent data from the Intergroup Francophone du Myélome, Cancer and…”
Get full text

TNF‐α inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature by Nair, Bijay, Raval, Girindra, Mehta, Paulette

“…We report here a 57‐year‐old man treated with etanercept for 6 months for psoriasis who developed myelodysplasia with acute myeloid leukemia. Leukemia cells…”
Get full text

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols by Hoering, Antje, Crowley, John, Shaughnessy, John D, Hollmig, Klaus, Alsayed, Yazan, Szymonifka, Jackie, Waheed, Sarah, Nair, Bijay, van Rhee, Frits, Anaissie, Elias, Barlogie, Bart

“…Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy. With…”
Get full text

Human Placenta‐Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone by Li, Xin, Ling, Wen, Pennisi, Angela, Wang, Yuping, Khan, Sharmin, Heidaran, Mohammad, Pal, Ajai, Zhang, Xiaokui, He, Shuyang, Zeitlin, Andy, Abbot, Stewart, Faleck, Herbert, Hariri, Robert, Shaughnessy, John D., van Rhee, Frits, Nair, Bijay, Barlogie, Bart, Epstein, Joshua, Yaccoby, Shmuel

“…Human placenta has emerged as a valuable source of transplantable cells of mesenchymal and hematopoietic origin for multiple cytotherapeutic purposes,…”
Get full text

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols by Usmani, S Z, Nair, B, Qu, P, Hansen, E, Zhang, Q, Petty, N, Waheed, S, Shaughnessy, J D, Alsayed, Y, Heuck, C J, van Rhee, F, Milner, T, Hoering, A, Szymonifka, J, Sexton, R, Sawyer, J, Singh, Z, Crowley, J, Barlogie, B

“…To determine whether primary plasma cell leukemia (PPCL) remains a high-risk multiple myeloma feature in the context of contemporary therapy and…”
Get full text